Next Article in Journal
Ocular and Systemic Manifestations in Paediatric Multisystem Inflammatory Syndrome Associated with COVID-19
Next Article in Special Issue
In Vitro Evaluation of the Antiviral Activity of Methylene Blue Alone or in Combination against SARS-CoV-2
Previous Article in Journal
Maternal Systemic Lupus Erythematosus (SLE) High Risk for Preterm Delivery and Not for Long-Term Neurological Morbidity of the Offspring
Previous Article in Special Issue
Evaluation of Strategies to Fight COVID-19: The French Paradigm
 
 
jcm-logo
Article Menu

Article Menu

Article

Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020

1
Institut Pasteur de Dakar, Dakar BP 220, Senegal
2
Service des Maladies Infectieuses et Tropicales, De Fann University Hospital Center (CNHU FANN), Dakar BP 5035, Senegal
3
Hôpital Principal de Dakar, Dakar BP 220, Senegal
4
Centre de Traitement des épidémies de l’Hôpital Dalal Jamm, Dakar BP 19.001, Senegal
5
Hôpital de Diamnadio, Centre de Traitement des épidémies de l’Hôpital de Diamnadio, Bargny BP 204, Senegal
6
Fann University Hospital, Centre de Traitement des épidémies de Touba, Touba 22300, Senegal
*
Author to whom correspondence should be addressed.
Academic Editors: Philippe Parola, Corneliu Petru Popescu and Emmanuel Andrès
J. Clin. Med. 2021, 10(13), 2954; https://doi.org/10.3390/jcm10132954
Received: 1 May 2021 / Revised: 23 June 2021 / Accepted: 28 June 2021 / Published: 30 June 2021
As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63, IC 95% (1.09–2.43)). Factors associated with a lower proportion of patients discharged alive were: age ≥ 60 years (OR: 0.55, IC 95% (0.36–0.83)), having of at least one pre-existing disorder (OR: 0.61, IC 95% (0.42–0.90)), and a high clinical risk at admission following NEWS score (OR: 0.49, IC 95% (0.28–0.83)). Few side effects were reported including 2 cases of cardiac rhythmic disorders in the HCQ and AZM group versus 13 in without HCQ + AZM. An improvement of clinical status at 15 days was found for patients exposed to HCQ plus AZM combination. View Full-Text
Keywords: SARS-CoV-2; hydroxychloroquine; azithromycin; treatment; Senegal SARS-CoV-2; hydroxychloroquine; azithromycin; treatment; Senegal
Show Figures

Figure 1

MDPI and ACS Style

Taieb, F.; Mbaye, K.D.; Tall, B.; Lakhe, N.A.; Talla, C.; Thioub, D.; Ndoye, A.M.; Ka, D.; Gaye, A.; Cissé Diallo, V.M.-P.; Dia, N.; Ba, P.S.; Cissé, M.; Diop, M.; Diagne, C.T.; Fortes, L.; Diop, M.; Fall, N.M.; Sarr, F.D.; Diatta, M.; Barry, M.A.; Badiane, A.S.; Seck, A.; Dubrous, P.; Faye, O.; Vigan-Womas, I.; Loucoubar, C.; Sall, A.A.; Seydi, M. Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. J. Clin. Med. 2021, 10, 2954. https://doi.org/10.3390/jcm10132954

AMA Style

Taieb F, Mbaye KD, Tall B, Lakhe NA, Talla C, Thioub D, Ndoye AM, Ka D, Gaye A, Cissé Diallo VM-P, Dia N, Ba PS, Cissé M, Diop M, Diagne CT, Fortes L, Diop M, Fall NM, Sarr FD, Diatta M, Barry MA, Badiane AS, Seck A, Dubrous P, Faye O, Vigan-Womas I, Loucoubar C, Sall AA, Seydi M. Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. Journal of Clinical Medicine. 2021; 10(13):2954. https://doi.org/10.3390/jcm10132954

Chicago/Turabian Style

Taieb, Fabien, Khardiata Diallo Mbaye, Billo Tall, Ndèye Aïssatou Lakhe, Cheikh Talla, Daouda Thioub, Amadou Moustapha Ndoye, Daye Ka, Aboubacry Gaye, Viviane Marie-Pierre Cissé Diallo, Ndongo Dia, Pape Samba Ba, Mamadou Cissé, Moustapha Diop, Cheikh Tidiane Diagne, Louise Fortes, Mamadou Diop, Ndèye Maguette Fall, Fatoumata Diène Sarr, Margarite Diatta, Mamadou Aliou Barry, Aboubakar Sidikh Badiane, Abdoulaye Seck, Philippe Dubrous, Ousmane Faye, Inès Vigan-Womas, Cheikh Loucoubar, Amadou Alpha Sall, and Moussa Seydi. 2021. "Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020" Journal of Clinical Medicine 10, no. 13: 2954. https://doi.org/10.3390/jcm10132954

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop